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Robin Christensen and colleagues' meta-analysis (Nov 17, p 1706)1 contains several inaccuracies that should be 
noted. 
The assertion that all patients with depressed mood were excluded from the RIO studies is incorrect. The 
protocols specifically excluded only patients with "clinically significant psychiatric disease and history of severe 
depression that could be defined as depression leading the patient to be hospitalised, or patients with two or more 
recurrent episodes of depression, or a history of suicide attempt". 
In figure 4, Christensen and colleagues' use of a combined composite endpoint for depressed-mood disorders for 
the RIO-Lipids study overestimates the true rates, since some patients might have had more than one depressive 
adverse event leading to treatment discontinuation. 
Christensen and colleagues' caution that some adverse events might not have been documented is unwarranted. 
All sites were revisited retrospectively to assess whether discontinuations not specifically ascribed to adverse 
event(s) were actually associated with adverse events. The relative risks of withdrawal for adverse events were 
unchanged. 
In discussing the US Food and Drug Administration Advisory Committee deliberations, Christensen and 
colleagues seem to confuse the terms "suicide" and "suicidality". Moreover, a higher rate of "suicidal ideation" 
has not clearly been shown to translate into a higher rate of suicide.2
The revised product label for rimonabant stresses the importance of selecting the appropriate patient 
population—ie, overweight or obese individuals with cardiometabolic risk factors and no major depressive 
illness or ongoing antidepressive treatment.3
Finally, Christensen and colleagues' assertion that "no follow-ups were reported after discontinuation of the 
active treatment,thus any weight regain could be not assessed" is incorrect. The weight regain issue was 
specifically addressed during the randomised double-blind withdrawal period in the second 12 months of the 
RIO-North America trial. Patients switching from rimonabant 5 mg or 20 mg to placebo regained weight to a 
level comparable with that of patients treated with nutritional recommendations alone for 2 years. Beneficial 
effects of rimonabant on bodyweight, waist circumference, HDL cholesterol, and triglycerides were maintained 
(in RIO-North America and RIO-Europe) during 2 years of continuous rimonabant treatment. These results show 
the absence of a "rebound" effect after discontinuation of rimonabant, and establish its long-term maintenance 
effect not only on bodyweight and waist but also on the cardiometabolic risk profile, and confirm the well 
established principle that, as with chronic diseases such as hypertension or diabetes, maintenance of efficacy 
requires treatment continuation. 
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